Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: Results of a phase III study

Arthritis and Rheumatology

Volumn 67, Issue 6, 2015, Pages 1424-1437

  Genovese, Mark C ^a   Fleischmann, Roy ^b   Kivitz, Alan J ^c   Rell Bakalarska, Maria ^d   Martincova, Renata ^e   Fiore, Stefano ^f   Rohane, Patricia ^f   Van Hoogstraten, Hubert ^f   Garg, Anju ^f   Fan, Chunpeng ^f   Van Adelsberg, Janet ^g   Weinstein, Steven P ^g   Graham, Neil M H ^g   Stahl, Neil ^g   Yancopoulos, George D ^g   Huizinga, Tom W J ^h   Van Der Heijde, Désirée ^h  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b METROPLEX CLINICAL RESEARCH CENTER   (United States)

^c Altoona Center for Clinical Research   (United States)

^d Rheumatology and Osteoporosis Outpatient Clinic   (Poland)

^e Sanofi Pasteur   (Czech Republic)

^f SANOFI   (France)

^g REGENERON PHARMACEUTICALS INC   (United States)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; C REACTIVE PROTEIN; METHOTREXATE; SARILUMAB; ANTIRHEUMATIC AGENT; INTERLEUKIN 6 RECEPTOR ALPHA; MONOCLONAL ANTIBODY;

ADULT; AGED; ANEMIA; ARTICLE; BRONCHITIS; CLINICAL DISEASE ACTIVITY INDEX; CONTROLLED STUDY; DAS28; DIARRHEA; DISEASE ACTIVITY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; HYPERTRANSAMINASEMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OPPORTUNISTIC INFECTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; ADOLESCENT; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG COMBINATION; HYPERCHOLESTEROLEMIA; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; INTERLEUKIN-6 RECEPTOR ALPHA SUBUNIT; MALE; METHOTREXATE; MIDDLE AGED; NEUTROPENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929881847     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39093     Document Type: Article

References (46)

1. Upchurch KS, Kay J., Evolution of treatment for rheumatoid arthritis. Rheumatology (Oxford) 2012; 51 Suppl 6: vi28-36.
2. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al., 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-39.
3. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73: 492-509.
4. Van der Heijde DM., Radiographic imaging: the 'gold standard' for assessment of disease progression in rheumatoid arthritis. Rheumatology (Oxford) 2000; 39 Suppl 1: 9-16.
5. Simsek I., TNF inhibitors: new and old agents for rheumatoid arthritis. Bull NYU Hosp Jt Dis 2010; 68: 204-10.
6. Singh JA, Cameron DR., Summary of AHRQ's comparative effectiveness review of drug therapy for rheumatoid arthritis (RA) in adults: an update. J Manag Care Pharm 2012; 18: S1-18.
7. Choy EH, Kavanaugh AF, Jones SA., The problem of choice: current biologic agents and future prospects in RA. Nat Rev Rheumatol 2013; 9: 154-63.
8. Srirangan S, Choy EH., The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskelet Dis 2010; 2: 247-56.
9. Matsumoto T, Tsurumoto T, Shindo H., Interleukin-6 levels in synovial fluids of patients with rheumatoid arthritis correlated with the infiltration of inflammatory cells in synovial membrane. Rheumatol Int 2006; 26: 1096-100.
10. Sugiyama E, Kuroda A, Hori F, Hori T, Taki H, Arai N, et al., Serum interleukin-6 level is a sensitive parameter of disease activity in rheumatoid arthritis. J Clin Rheumatol 1995; 1: 93-8.
11. Macdonald LE, Karow M, Stevens S, Auerbach W, Poueymirou WT, Yasenchak J, et al., Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci U S A 2014; 111: 5147-52.
12. Murphy AJ, Macdonald LE, Stevens S, Karow M, Dore AT, Pobursky K, et al., Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A 2014; 111: 5153-8.
13. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al., IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008; 67: 1516-23.
14. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al., Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy study. Arthritis Rheum 2008; 58: 2968-80.
15. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al., Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010; 69: 88-96.
16. Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, et al., Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011; 63: 609-21.
17. Smolen JS, Avila JC, Aletaha D., Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. Ann Rheum Dis 2012; 71: 687-93.
18. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al., Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371: 987-97.
19. Huizinga TW, Fleischmann RM, Jasson M, Radin AR, van Adelsberg J, Fiore S, et al., Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis 2014; 73: 1626-34.
20. Rafique A, Martin J, Blome M, Huang T, Ouyang A, Papadopoulos N,. Evaluation of the binding kinetics and functional bioassay activity of sarilumab and tocilizumab to the human IL-6 receptor (IL-6R) α. Ann Rheum Dis 2013; 72 Suppl 3: 797.
21. Wang LH, Xue Y, Liu X, Luo F, Kelly L, Huang T, et al., Preclinical development of sarilumab, the first fully human monoclonal antibody (mAb) against IL-6Rα: utilization and value of double humanized animal model. Ann Rheum Dis 2013; 72 Suppl 3: 375.
22. Zhang L, Luan B, Adler A, Eichten A, Daly C, Thurston G,. Sarilumab (REGN88), a fully-human anti-IL6R antibody, inhibits tumor growth in preclinical models, as a single agent and in combination with the VEGF blocker aflibercept [abstract]. Cancer Res 2012; 72 Suppl 8: 2723.
23. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
24. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al., The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36: 729-40.
25. Van der Heijde DM,. How to read radiographs according to the Sharp/van der Heijde method [corrected and republished in J Rheumatol 2000;27:261-3]. J Rheumatol 1999; 26: 743-5.
26. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al., American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
27. Fries JF, Spitz P, Kraines RG, Holman HR., Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
28. US Food and Drug Administration. Guidance for industry: clinical development programs for drugs, devices, and biological products for the treatment of rheumatoid arthritis (RA). February 1999. URL: http://www.fda.gov/downloads/Drugs/Guidances/ucm071579.pdf.
29. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL., Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
30. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al., Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005; 7: R796-806.
31. Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, et al., Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 2014; 73: 86-94.
32. Lillegraven S, van der Heijde D, Uhlig T, Kvien TK, Haavardsholm EA., What is the clinical relevance of erosions and joint space narrowing in RA? Nat Rev Rheumatol 2012; 8: 117-20.
33. Van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al, and the ORAL Scan Investigators. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013; 65: 559-70.
34. Rahman MU, Buchanan J, Doyle MK, Hsia EC, Gathany T, Parasuraman S, et al., Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years. Ann Rheum Dis 2011; 70: 1631-40.
35. Aletaha D, Smolen J., The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23 Suppl 39: S100-8.
36. Choy E., Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 2012; 51 Suppl 5: v3-11.
37. Navarro G, Taroumian S, Barroso N, Duan L, Furst D., Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums. Semin Arthritis Rheum 2014; 43: 458-69.
38. Cohen S, Radominski SC, Gomez-Reino JJ, Wang L, Krishnaswami S, Wood SP, et al., Analysis of infections and all-cause mortality in Phase II, III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol 2014; 66: 2924-37.
39. Singh JA, Beg S, Lopez-Olivo MA., Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol 2011; 38: 10-20.
40. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, Pollono EN, Cueto JP, Gonzales-Crespo MR, et al., Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 2012; 308: 898-908.
41. Cuffe RL, Lawrence D, Stone A, Vandemeulebroecke M., When is a seamless study desirable? Case studies from different pharmaceutical sponsors. Pharm Stat 2014; 13: 229-37.
42. Kunz CU, Friede T, Parsons N, Todd S, Stallard N., Data-driven treatment selection for seamless phase II/III trials incorporating early-outcome data. Pharm Stat 2014; 13: 238-46.
43. Campbell L, Chen C, Bhagat SS, Parker RA, Ostor AJ., Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford) 2011; 50: 552-62.
44. Genovese MC, Fleischmann R, Furst D, Janssen N, Carter J, Dasgupta B, et al., Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis 2014; 73: 1607-15.
45. Mease P, Strand V, Shalamberidze L, Dimic A, Raskina T, Xu LA, et al., A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann Rheum Dis 2012; 71: 1183-9.
46. Smolen JS, Weinblatt ME, Sheng S, Zhuang Y, Hsu B., Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2014; 73: 1616-25.